New drug cocktail aims to zap lung cancer before surgery
NCT ID NCT07642024
First seen Jun 12, 2026 · Last updated Jun 23, 2026 · Updated 4 times
Summary
This study tests a new drug called BL-B01D1 combined with the standard pill osimertinib in people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer) that can be removed with surgery. The goal is to see if giving this combination before surgery shrinks tumors more effectively. About 90 participants will be randomly assigned to receive the combo or standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Contact
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-B01D1 (a drug given by IV) combined with osimertinib (a pill)
What this could lead to
If successful, this combination could become a new standard treatment before surgery for EGFR-mutated lung cancer, potentially improving survival and reducing recurrence.
What could go wrong
This is an early-to-mid stage trial with only 90 participants. The combination may cause significant side effects, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.